Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 37 | 2023 | 1386 | 6.590 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 32 | 2024 | 1427 | 2.910 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 65 | 2024 | 11843 | 2.440 |
Why?
|
Lymphoma, Non-Hodgkin | 25 | 2021 | 1376 | 2.430 |
Why?
|
Lymphoma, Follicular | 10 | 2024 | 460 | 1.800 |
Why?
|
Burkitt Lymphoma | 6 | 2021 | 336 | 1.570 |
Why?
|
Stem Cell Transplantation | 18 | 2023 | 1602 | 1.310 |
Why?
|
Lymphoma, Mantle-Cell | 11 | 2020 | 238 | 1.300 |
Why?
|
Vincristine | 22 | 2024 | 1039 | 1.270 |
Why?
|
Salvage Therapy | 9 | 2020 | 1277 | 1.180 |
Why?
|
Lymphoma, B-Cell | 9 | 2021 | 945 | 1.160 |
Why?
|
Doxorubicin | 28 | 2024 | 2229 | 1.140 |
Why?
|
Transplantation, Autologous | 20 | 2023 | 2126 | 1.120 |
Why?
|
Cyclophosphamide | 28 | 2024 | 2224 | 1.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 19 | 2014 | 695 | 1.010 |
Why?
|
Positron-Emission Tomography | 21 | 2022 | 6657 | 0.920 |
Why?
|
Lymphoma | 11 | 2023 | 1907 | 0.890 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2024 | 1644 | 0.850 |
Why?
|
Herpesvirus 4, Human | 5 | 2021 | 1081 | 0.840 |
Why?
|
Vinblastine | 11 | 2023 | 488 | 0.780 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2021 | 616 | 0.760 |
Why?
|
Prednisone | 16 | 2024 | 1568 | 0.750 |
Why?
|
Dacarbazine | 10 | 2023 | 560 | 0.690 |
Why?
|
Mediastinal Neoplasms | 6 | 2018 | 403 | 0.680 |
Why?
|
Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5709 | 0.660 |
Why?
|
Education, Graduate | 1 | 2019 | 75 | 0.620 |
Why?
|
Lymphoma, T-Cell | 2 | 2014 | 304 | 0.600 |
Why?
|
Disease-Free Survival | 31 | 2023 | 6856 | 0.580 |
Why?
|
Music Therapy | 3 | 2023 | 111 | 0.550 |
Why?
|
Etoposide | 13 | 2020 | 640 | 0.550 |
Why?
|
Lymphoproliferative Disorders | 3 | 2010 | 531 | 0.530 |
Why?
|
Immune Evasion | 1 | 2019 | 377 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 2018 | 998 | 0.500 |
Why?
|
Fellowships and Scholarships | 3 | 2022 | 1134 | 0.480 |
Why?
|
Neoplasm Staging | 25 | 2024 | 11249 | 0.470 |
Why?
|
Bleomycin | 8 | 2023 | 495 | 0.460 |
Why?
|
Fluorodeoxyglucose F18 | 9 | 2016 | 2048 | 0.460 |
Why?
|
Immunoconjugates | 3 | 2018 | 968 | 0.460 |
Why?
|
Lymph Nodes | 3 | 2023 | 3472 | 0.440 |
Why?
|
Recurrence | 19 | 2023 | 8510 | 0.440 |
Why?
|
Radiopharmaceuticals | 7 | 2017 | 2731 | 0.430 |
Why?
|
Transplantation Conditioning | 9 | 2023 | 1598 | 0.430 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2014 | 168 | 0.430 |
Why?
|
Humans | 161 | 2024 | 768451 | 0.430 |
Why?
|
Hematology | 3 | 2022 | 244 | 0.420 |
Why?
|
Lymphoma, T-Cell, Peripheral | 3 | 2023 | 126 | 0.420 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 193 | 0.410 |
Why?
|
Career Choice | 1 | 2019 | 769 | 0.410 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2012 | 120 | 0.390 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2014 | 290 | 0.390 |
Why?
|
Antibodies | 1 | 2019 | 2425 | 0.380 |
Why?
|
Prognosis | 26 | 2024 | 30028 | 0.370 |
Why?
|
Vidarabine | 2 | 2024 | 337 | 0.350 |
Why?
|
Antineoplastic Agents | 21 | 2023 | 13708 | 0.350 |
Why?
|
Adult | 78 | 2024 | 223542 | 0.340 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 180 | 0.330 |
Why?
|
Treatment Outcome | 42 | 2024 | 65409 | 0.320 |
Why?
|
Combined Modality Therapy | 12 | 2024 | 8559 | 0.310 |
Why?
|
Cytarabine | 8 | 2020 | 697 | 0.310 |
Why?
|
Referral and Consultation | 2 | 2014 | 3629 | 0.310 |
Why?
|
Female | 89 | 2024 | 396943 | 0.300 |
Why?
|
Antibodies, Monoclonal | 8 | 2023 | 9263 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2023 | 9425 | 0.300 |
Why?
|
Male | 89 | 2024 | 364781 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2022 | 1409 | 0.300 |
Why?
|
Disease Management | 4 | 2024 | 2533 | 0.280 |
Why?
|
Medication Adherence | 1 | 2018 | 2190 | 0.270 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1797 | 0.270 |
Why?
|
Middle Aged | 74 | 2024 | 223418 | 0.270 |
Why?
|
Heart Neoplasms | 1 | 2010 | 374 | 0.270 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1628 | 0.270 |
Why?
|
Protein Kinase C | 2 | 2008 | 1207 | 0.270 |
Why?
|
Medical Oncology | 4 | 2019 | 2347 | 0.260 |
Why?
|
Protein Kinase Inhibitors | 7 | 2019 | 5709 | 0.260 |
Why?
|
Neoplasm Proteins | 4 | 2021 | 3611 | 0.260 |
Why?
|
Anthracyclines | 2 | 2023 | 286 | 0.250 |
Why?
|
Cancer Care Facilities | 1 | 2008 | 424 | 0.250 |
Why?
|
Sarcoma, Kaposi | 2 | 2019 | 374 | 0.250 |
Why?
|
Tomography, X-Ray Computed | 14 | 2023 | 20762 | 0.250 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 928 | 0.250 |
Why?
|
Vascular Diseases | 1 | 2013 | 1162 | 0.240 |
Why?
|
Pyrazines | 3 | 2021 | 1206 | 0.240 |
Why?
|
Aged | 64 | 2024 | 171520 | 0.240 |
Why?
|
Immunotherapy, Adoptive | 2 | 2019 | 1505 | 0.240 |
Why?
|
Survival Rate | 15 | 2021 | 12875 | 0.230 |
Why?
|
Transplants | 1 | 2006 | 208 | 0.220 |
Why?
|
Recombinant Fusion Proteins | 1 | 2012 | 3735 | 0.220 |
Why?
|
Ifosfamide | 4 | 2014 | 234 | 0.210 |
Why?
|
Organ Transplantation | 2 | 2010 | 1177 | 0.210 |
Why?
|
Indoles | 2 | 2008 | 1834 | 0.210 |
Why?
|
Young Adult | 26 | 2024 | 60045 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2019 | 5342 | 0.210 |
Why?
|
Survival Analysis | 10 | 2020 | 10125 | 0.200 |
Why?
|
Immunologic Factors | 2 | 2009 | 1600 | 0.200 |
Why?
|
Neoplasms | 8 | 2024 | 22386 | 0.200 |
Why?
|
Lymphocytes | 1 | 2009 | 2611 | 0.190 |
Why?
|
Methotrexate | 5 | 2014 | 1722 | 0.190 |
Why?
|
Transplantation, Homologous | 7 | 2023 | 4834 | 0.190 |
Why?
|
Tumor Lysis Syndrome | 1 | 2021 | 38 | 0.190 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 895 | 0.180 |
Why?
|
Histiocytes | 1 | 2021 | 98 | 0.180 |
Why?
|
Oxazines | 2 | 2015 | 357 | 0.180 |
Why?
|
Cancer Vaccines | 2 | 2024 | 1044 | 0.180 |
Why?
|
Carmustine | 3 | 2020 | 137 | 0.180 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 8051 | 0.180 |
Why?
|
Adenine | 2 | 2024 | 993 | 0.180 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1484 | 0.180 |
Why?
|
Retreatment | 2 | 2019 | 601 | 0.170 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39430 | 0.170 |
Why?
|
Piperidines | 3 | 2024 | 1664 | 0.170 |
Why?
|
Radiotherapy | 5 | 2016 | 1510 | 0.170 |
Why?
|
Neoplasm, Residual | 6 | 2023 | 1014 | 0.170 |
Why?
|
Music | 1 | 2023 | 247 | 0.170 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.170 |
Why?
|
Endemic Diseases | 1 | 2021 | 191 | 0.170 |
Why?
|
Genes, myc | 1 | 2021 | 391 | 0.170 |
Why?
|
Adolescent | 26 | 2024 | 89168 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 679 | 0.170 |
Why?
|
Drug Administration Schedule | 9 | 2021 | 4861 | 0.160 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 271 | 0.160 |
Why?
|
Neutropenia | 2 | 2023 | 892 | 0.160 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2024 | 716 | 0.150 |
Why?
|
Private Practice | 1 | 2019 | 155 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2016 | 190 | 0.150 |
Why?
|
Angiogenesis Inhibitors | 1 | 2008 | 2062 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 750 | 0.150 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 13026 | 0.150 |
Why?
|
Tumor Escape | 1 | 2021 | 374 | 0.150 |
Why?
|
Neoplasms, Second Primary | 5 | 2017 | 1062 | 0.150 |
Why?
|
Heart | 2 | 2010 | 4451 | 0.150 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2643 | 0.150 |
Why?
|
Immunohistochemistry | 7 | 2014 | 11138 | 0.150 |
Why?
|
Remission Induction | 7 | 2021 | 2408 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3543 | 0.140 |
Why?
|
Sulfonamides | 2 | 2021 | 1988 | 0.140 |
Why?
|
Time Factors | 8 | 2021 | 40271 | 0.140 |
Why?
|
Myocardium | 1 | 2010 | 4788 | 0.140 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 419 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1557 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 849 | 0.140 |
Why?
|
Paclitaxel | 1 | 2024 | 1737 | 0.140 |
Why?
|
Aged, 80 and over | 26 | 2018 | 59680 | 0.140 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2018 | 330 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Pyridines | 3 | 2015 | 2888 | 0.130 |
Why?
|
Boronic Acids | 2 | 2010 | 915 | 0.130 |
Why?
|
Heart Diseases | 3 | 2023 | 2816 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-rel | 2 | 2007 | 71 | 0.130 |
Why?
|
Herpesvirus 8, Human | 1 | 2018 | 256 | 0.130 |
Why?
|
Gene Rearrangement | 2 | 2018 | 1139 | 0.130 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2017 | 187 | 0.130 |
Why?
|
Databases, Factual | 1 | 2012 | 8081 | 0.130 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2017 | 225 | 0.130 |
Why?
|
Pyrimidines | 4 | 2019 | 3050 | 0.130 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 3042 | 0.130 |
Why?
|
Age Factors | 5 | 2019 | 18478 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1381 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2018 | 376 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Cohort Studies | 12 | 2016 | 41797 | 0.120 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 664 | 0.120 |
Why?
|
Retrospective Studies | 25 | 2023 | 81834 | 0.120 |
Why?
|
Immunophenotyping | 3 | 2016 | 1869 | 0.120 |
Why?
|
Exanthema | 1 | 2019 | 504 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2019 | 2964 | 0.120 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 13 | 0.120 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 40 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 618 | 0.110 |
Why?
|
Sequence Deletion | 1 | 2018 | 1497 | 0.110 |
Why?
|
Europe | 1 | 2021 | 3439 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1390 | 0.110 |
Why?
|
Mentors | 1 | 2019 | 672 | 0.110 |
Why?
|
Prednisolone | 2 | 2018 | 327 | 0.110 |
Why?
|
Central Nervous System | 1 | 2021 | 1348 | 0.110 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 155 | 0.110 |
Why?
|
Immunotherapy | 4 | 2024 | 4728 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 3 | 2017 | 1400 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2884 | 0.100 |
Why?
|
Carotid Artery, Common | 1 | 2013 | 175 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2834 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9507 | 0.100 |
Why?
|
Herpes Zoster | 1 | 2015 | 253 | 0.100 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 111 | 0.100 |
Why?
|
Vaccination | 1 | 2024 | 3434 | 0.100 |
Why?
|
United States | 10 | 2021 | 73121 | 0.100 |
Why?
|
Viral Load | 3 | 2018 | 3399 | 0.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2017 | 1903 | 0.090 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 103 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2016 | 631 | 0.090 |
Why?
|
HIV Infections | 5 | 2018 | 17564 | 0.090 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1320 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2017 | 806 | 0.090 |
Why?
|
Hydrocephalus | 1 | 2017 | 770 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1806 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1905 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4077 | 0.090 |
Why?
|
Antigens, CD | 1 | 2021 | 4029 | 0.090 |
Why?
|
Fever | 1 | 2017 | 1622 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1260 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1395 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2024 | 0.080 |
Why?
|
Specimen Handling | 1 | 2013 | 709 | 0.080 |
Why?
|
Hospice Care | 1 | 2015 | 679 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10273 | 0.080 |
Why?
|
Comorbidity | 5 | 2018 | 10601 | 0.080 |
Why?
|
Procarbazine | 2 | 2019 | 172 | 0.080 |
Why?
|
Child | 10 | 2023 | 80863 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.080 |
Why?
|
Preoperative Care | 1 | 2017 | 2257 | 0.080 |
Why?
|
Tachycardia | 1 | 2010 | 599 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 6 | 2017 | 6537 | 0.070 |
Why?
|
Leukemia | 1 | 2016 | 1527 | 0.070 |
Why?
|
Medical Errors | 1 | 2016 | 1263 | 0.070 |
Why?
|
Watchful Waiting | 1 | 2012 | 496 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3619 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4781 | 0.070 |
Why?
|
Treatment Failure | 2 | 2012 | 2656 | 0.070 |
Why?
|
Helicobacter pylori | 1 | 2011 | 382 | 0.070 |
Why?
|
Antigens, CD20 | 1 | 2008 | 199 | 0.070 |
Why?
|
TNF Receptor-Associated Factor 1 | 1 | 2007 | 48 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 1 | 2013 | 1434 | 0.070 |
Why?
|
Bone Marrow Cells | 2 | 2013 | 2415 | 0.070 |
Why?
|
Databases as Topic | 1 | 2008 | 475 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2008 | 355 | 0.070 |
Why?
|
Troponin | 1 | 2010 | 534 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 958 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1855 | 0.060 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 249 | 0.060 |
Why?
|
Aorta | 1 | 2013 | 2046 | 0.060 |
Why?
|
Sirolimus | 2 | 2012 | 1542 | 0.060 |
Why?
|
Piperazines | 2 | 2016 | 2546 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2015 | 2434 | 0.060 |
Why?
|
Oligonucleotides | 1 | 2008 | 564 | 0.060 |
Why?
|
Aniline Compounds | 1 | 2010 | 1094 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7863 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2011 | 1276 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4419 | 0.060 |
Why?
|
Registries | 2 | 2013 | 8373 | 0.060 |
Why?
|
Mesna | 1 | 2004 | 62 | 0.060 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2011 | 887 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 3623 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2882 | 0.060 |
Why?
|
Administration, Oral | 3 | 2019 | 4041 | 0.060 |
Why?
|
Research Personnel | 1 | 2008 | 591 | 0.060 |
Why?
|
Sex Distribution | 1 | 2009 | 2286 | 0.060 |
Why?
|
Lymphocyte Count | 2 | 2018 | 793 | 0.050 |
Why?
|
Macrophages | 1 | 2018 | 5797 | 0.050 |
Why?
|
Thiazoles | 1 | 2011 | 1541 | 0.050 |
Why?
|
Thiotepa | 2 | 2014 | 66 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2014 | 5904 | 0.050 |
Why?
|
K562 Cells | 1 | 2024 | 645 | 0.050 |
Why?
|
Switzerland | 1 | 2023 | 322 | 0.050 |
Why?
|
Pregnancy | 1 | 2024 | 30179 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2008 | 3594 | 0.050 |
Why?
|
Busulfan | 2 | 2014 | 259 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2622 | 0.050 |
Why?
|
Leucovorin | 1 | 2004 | 643 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9505 | 0.050 |
Why?
|
Risk Factors | 9 | 2021 | 74915 | 0.050 |
Why?
|
Population Surveillance | 1 | 2012 | 2601 | 0.050 |
Why?
|
Hematologic Diseases | 2 | 2019 | 499 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 10358 | 0.050 |
Why?
|
DNA, Viral | 2 | 2018 | 2206 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3858 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 624 | 0.040 |
Why?
|
NAD | 1 | 2024 | 618 | 0.040 |
Why?
|
Child, Preschool | 3 | 2018 | 42623 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2008 | 1969 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15460 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7451 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 750 | 0.040 |
Why?
|
Pneumonia | 1 | 2012 | 2162 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 3637 | 0.040 |
Why?
|
SEER Program | 2 | 2015 | 1476 | 0.040 |
Why?
|
Morpholines | 2 | 2015 | 583 | 0.040 |
Why?
|
Mediastinum | 2 | 2012 | 273 | 0.040 |
Why?
|
HIV-1 | 2 | 2017 | 6966 | 0.040 |
Why?
|
DNA | 1 | 2013 | 7213 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12450 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2465 | 0.040 |
Why?
|
Data Collection | 1 | 2008 | 3329 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2238 | 0.040 |
Why?
|
Mutation | 2 | 2021 | 30243 | 0.040 |
Why?
|
Aminopyridines | 2 | 2015 | 578 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6816 | 0.040 |
Why?
|
Disease Progression | 5 | 2015 | 13655 | 0.040 |
Why?
|
Thalidomide | 2 | 2014 | 885 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2023 | 810 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8753 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 890 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2007 | 2889 | 0.040 |
Why?
|
Podophyllotoxin | 1 | 2017 | 20 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4655 | 0.040 |
Why?
|
Prospective Studies | 6 | 2020 | 54914 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3520 | 0.030 |
Why?
|
Methylprednisolone | 1 | 2018 | 387 | 0.030 |
Why?
|
Phosphorylation | 1 | 2008 | 8332 | 0.030 |
Why?
|
Stress, Psychological | 2 | 2023 | 4538 | 0.030 |
Why?
|
NF-kappa B | 1 | 2005 | 2491 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 648 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1678 | 0.030 |
Why?
|
Games, Experimental | 1 | 2016 | 32 | 0.030 |
Why?
|
Fatigue | 2 | 2014 | 1556 | 0.030 |
Why?
|
Anemia | 2 | 2018 | 1521 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Curriculum | 2 | 2022 | 3778 | 0.030 |
Why?
|
Melphalan | 1 | 2017 | 420 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4213 | 0.030 |
Why?
|
Radiotherapy Dosage | 2 | 2012 | 2925 | 0.030 |
Why?
|
Apoptosis | 2 | 2008 | 9526 | 0.030 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 1995 | 284 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 354 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 351 | 0.030 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2014 | 93 | 0.030 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 105 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14766 | 0.030 |
Why?
|
Herpesvirus 3, Human | 1 | 2015 | 159 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1421 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 369 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 716 | 0.030 |
Why?
|
Patient Selection | 2 | 2018 | 4266 | 0.030 |
Why?
|
Boston | 2 | 2021 | 9361 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2008 | 20231 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10784 | 0.030 |
Why?
|
Chemokines | 1 | 2017 | 963 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1672 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 245 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 921 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 867 | 0.030 |
Why?
|
Lung | 1 | 2011 | 10090 | 0.030 |
Why?
|
Phagocytosis | 1 | 2018 | 1531 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 755 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 159 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 369 | 0.030 |
Why?
|
Hepatitis B Antibodies | 1 | 2013 | 155 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1794 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2017 | 0.020 |
Why?
|
Lymphopenia | 1 | 2014 | 290 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 313 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1727 | 0.020 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 294 | 0.020 |
Why?
|
Qualitative Research | 1 | 2023 | 3115 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 2702 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2399 | 0.020 |
Why?
|
Nausea | 1 | 2014 | 682 | 0.020 |
Why?
|
HIV | 1 | 2018 | 1596 | 0.020 |
Why?
|
Signal Transduction | 2 | 2019 | 23638 | 0.020 |
Why?
|
Gonads | 1 | 2011 | 109 | 0.020 |
Why?
|
Dosage Forms | 1 | 2010 | 56 | 0.020 |
Why?
|
Virus Activation | 1 | 2013 | 322 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 252 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2013 | 490 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 839 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5308 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3941 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12096 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3939 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2011 | 642 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13324 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 132 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2411 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2228 | 0.020 |
Why?
|
Virus Replication | 1 | 2017 | 2459 | 0.020 |
Why?
|
Hepatitis B virus | 1 | 2013 | 530 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5620 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2012 | 352 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2005 | 8635 | 0.020 |
Why?
|
RNA, Viral | 1 | 2017 | 2865 | 0.020 |
Why?
|
Educational Measurement | 1 | 2016 | 1256 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8908 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 798 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4120 | 0.020 |
Why?
|
Teaching | 1 | 2016 | 1174 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8730 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2525 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1131 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2012 | 564 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2012 | 1775 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4642 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 541 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 236 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2058 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1296 | 0.020 |
Why?
|
Hepatitis B | 1 | 2013 | 707 | 0.020 |
Why?
|
Leukocytes | 1 | 1995 | 2030 | 0.020 |
Why?
|
Incidence | 3 | 2015 | 21552 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2575 | 0.020 |
Why?
|
Medicare | 2 | 2015 | 6881 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1937 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 9066 | 0.020 |
Why?
|
Social Class | 1 | 2015 | 2000 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 5495 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2011 | 888 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3708 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1614 | 0.020 |
Why?
|
Heterozygote | 1 | 2013 | 2792 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1395 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3955 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1881 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 2987 | 0.020 |
Why?
|
Transplantation Chimera | 1 | 2008 | 594 | 0.020 |
Why?
|
Gene Deletion | 1 | 2013 | 2674 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1479 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4534 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3108 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1668 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3123 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2847 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1337 | 0.010 |
Why?
|
Thrombosis | 1 | 2017 | 2956 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3342 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9687 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36840 | 0.010 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1794 | 0.010 |
Why?
|
Medical Records | 1 | 2008 | 1413 | 0.010 |
Why?
|
Palliative Care | 1 | 2018 | 3644 | 0.010 |
Why?
|
Diarrhea | 1 | 2009 | 1320 | 0.010 |
Why?
|
Hepatitis C | 1 | 2013 | 1594 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3412 | 0.010 |
Why?
|
Neutrophils | 1 | 1995 | 3790 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2018 | 4567 | 0.010 |
Why?
|
Lung Transplantation | 1 | 2011 | 1310 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10647 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6217 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6527 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2485 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9623 | 0.010 |
Why?
|
Heart Failure | 1 | 2023 | 11857 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 13030 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16712 | 0.010 |
Why?
|
Karyotyping | 1 | 1999 | 1173 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15880 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9382 | 0.010 |
Why?
|
Inflammation | 1 | 1995 | 10865 | 0.010 |
Why?
|
Risk Assessment | 2 | 2011 | 24311 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15965 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 14158 | 0.010 |
Why?
|
Peritonitis | 1 | 1995 | 368 | 0.010 |
Why?
|
P-Selectin | 1 | 1995 | 599 | 0.010 |
Why?
|
Mice | 2 | 2016 | 82045 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14728 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1995 | 1604 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15880 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8611 | 0.010 |
Why?
|
Cell Adhesion | 1 | 1995 | 3103 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17149 | 0.000 |
Why?
|
Animals | 2 | 2016 | 169418 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 18048 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1995 | 4425 | 0.000 |
Why?
|
Mice, Knockout | 1 | 1995 | 14480 | 0.000 |
Why?
|